Kyle Faget Authors Article on Considerations for Mobile Health Technology Developers
September 28, 2022
pharmaphorum
Foley & Lardner LLP Partner Kyle Faget authored the article, “Considerations for Mobile Health Technology Developers: Part 1,” published by pharmaphorum, about the U.S. Food and Drug Administration (FDA)’s common approach to regulating mHealth products, general wellness devices, and mobile medical applications.
Faget says, “Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to (FDA) regulation as a medical device. If so, developers must develop and execute on a regulatory strategy.”
Part 2 of this series will be devoted to clinical decision support (CDS) software.
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“